Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	114.83	295.61	74.47	222.08	115.36	24.61
Short-Term Investments	328.55	282.19	410.04	224.87	177.82	35.17
Cash & Cash Equivalents	443.38	577.8	484.51	446.95	293.18	59.78
Cash Growth	1.15%	19.25%	8.41%	52.45%	390.47%	-26.21%
Receivables	6.07	0	3.47	0	0	0
Other Current Assets	4.45	3.08	1.8	1.45	5.68	2.56
Total Current Assets	453.9	580.88	489.79	448.4	298.86	62.33
Property, Plant & Equipment	1.25	1.5	1.06	1.26	0.48	1
Long-Term Investments	87.42	29.83	5.47	0	0	0
Other Long-Term Assets	0.47	0.68	0.92	0	1.27	0.2
Total Long-Term Assets	89.13	32	7.45	1.26	1.75	1.19
Total Assets	543.03	612.88	497.24	449.66	300.61	63.53
Accounts Payable	16.36	17.19	4.35	5.67	3.51	6.18
Deferred Revenue	0	0	0	0	13.13	14.65
Current Debt	1.05	1.05	0.44	0.36	2.6	0.48
Other Current Liabilities	33.4	39.86	24.28	14.65	-0.37	-2.94
Total Current Liabilities	50.81	58.1	29.07	20.68	18.87	18.37
Long-Term Debt	0.33	0.59	0.72	20.61	17.94	0.42
Other Long-Term Liabilities	0	0	0	0	11.62	13.14
Total Long-Term Liabilities	0.33	0.59	0.72	20.61	29.55	13.56
Total Liabilities	51.14	58.68	29.79	41.29	48.43	31.93
Total Debt	1.39	1.64	1.16	20.97	20.54	0.9
Debt Growth	31.07%	40.83%	-94.46%	2.10%	2189.41%	-
Retained Earnings	-974.8	-902.4	-693.04	-543.7	-568.63	-495.47
Comprehensive Income	-0.76	0.22	-0.81	0.05	-0	0
Shareholders' Equity	491.89	554.2	467.45	408.37	252.19	31.6
Net Cash / Debt	441.99	576.17	483.35	425.98	272.64	58.88
Net Cash / Debt Growth	1.08%	19.20%	13.47%	56.24%	363.07%	-27.32%
Net Cash Per Share	5.19	8.19	7.95	7.94	6.60	1.93
Working Capital	403.09	522.78	460.72	427.71	279.99	43.96
Book Value Per Share	5.77	7.88	7.69	7.84	6.11	1.04

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).